Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222527 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL31677104 | 0.79 | PSMB8 (0.58) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL2162639 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL3081165 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL244929 | 0.79 | PSMB8 (0.58) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| Lithium SCHEMBL15812806 | 0.78 | PSMB8 (0.56) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL6209371 | 0.75 | TRPV1 (0.51) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL5398 | 0.71 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL2589250 | 0.71 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKDM4ETP53 | |
| SCHEMBL172216 | 0.70 | NPC1 (1.00) | ALDH1A1NPC1RAB9AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | TAIJI BIOMEDICAL, INC. | 2015-07-23 | — | — | US | claimed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | claimed |
| EP-2211856-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | The Hospital For Sick Children (CA) | 2010-08-04 | — | — | EP | claimed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-25 | — | — | US | claimed |
| WO-2009073564-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-11 | — | — | WO | claimed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | claimed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | claimed |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | TAIJI BIOMEDICAL, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9023845-B2 | Compositions and methods for treating lysosomal disorders | NEURALTUS PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | ALDH1A1 2806/4885NPC1 15/4885RAB9A 252/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ALDH1A1 2054/4885NPC1 153/4885RAB9A 759/4885 |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | GAA, GBA1, LIPA | ALDH1A1 2806/4885NPC1 15/4885RAB9A 252/4885 |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ALDH1A1 1641/4885NPC1 45/4885RAB9A 1628/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | ALDH1A1 1805/4885NPC1 62/4885RAB9A 2063/4885 |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | ALDH1A1 2806/4885NPC1 15/4885RAB9A 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.